Enanta Pharmaceuticals, Inc.

ENTA

US29251M1062

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 01:00:00 2024-07-03 pm EDT			5-day change	1st Jan Change
13.14 ^USD	-2.30%		+3.71%	+39.64%

Jul. 01	Enanta Pharmaceuticals, Inc.(NasdaqGS:ENTA) added to Russell 3000E Index	CI
Jul. 01	Enanta Pharmaceuticals, Inc.(NasdaqGS:ENTA) dropped from Russell 3000 Growth Index	CI

Enanta Pharmaceuticals, Inc.(NasdaqGS:ENTA) added to Russell 3000E Index

July 30, 2024

Latest news about Enanta Pharmaceuticals, Inc.

Enanta Pharmaceuticals, Inc.(NasdaqGS:ENTA) added to Russell 3000E Index	Jun. 30	CI
Enanta Pharmaceuticals, Inc.(NasdaqGS:ENTA) dropped from Russell 3000 Growth Index	Jun. 30	CI
Enanta Pharmaceuticals, Inc.(NasdaqGS:ENTA) added to Russell Microcap Index	Jun. 30	CI
Enanta Pharmaceuticals, Inc.(NasdaqGS:ENTA) dropped from Russell 3000E Growth Index	Jun. 30	CI
Enanta Pharmaceuticals, Inc.(NasdaqGS:ENTA) dropped from Russell 2000 Growth Index	Jun. 30	CI
Enanta Pharmaceuticals, Inc.(NasdaqGS:ENTA) added to Russell Microcap Value Index	Jun. 30	CI
Enanta Pharmaceuticals, Inc.(NasdaqGS:ENTA) dropped from Russell 2500 Growth Index	Jun. 30	CI
Enanta Pharmaceuticals, Inc.(NasdaqGS:ENTA) dropped from Russell Small Cap Comp Growth Index	Jun. 30	CI
Enanta Pharmaceuticals, Inc.(NasdaqGS:ENTA) added to Russell 3000E Value Index	Jun. 30	CI
JMP Securities Adjusts Enanta Pharmaceuticals Price Target to $22 From $23, Maintains Market Outperform Rating	May. 07	MT
Transcript : Enanta Pharmaceuticals, Inc., Q2 2024 Earnings Call, May 06, 2024	May. 06
Earnings Flash (ENTA) ENANTA PHARMACEUTICALS Posts Q2 Revenue $17.1M, vs. Street Est of $16.2M	May. 06	MT
Enanta Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	May. 06	CI
Enanta Pharmaceuticals, Inc. Appoints Matthew P. Kowalsky as Chief Legal Officer	Apr. 30	CI
Oppenheimer Adjusts Enanta Pharmaceuticals Price Target to $17 From $21, Maintains Perform Rating	Feb. 09	MT
Transcript : Enanta Pharmaceuticals, Inc., Q1 2024 Earnings Call, Feb 07, 2024	Feb. 07
Earnings Flash (ENTA) ENANTA PHARMACEUTICALS Reports Q1 Revenue $18M, vs. Street Est of $21.9M	Feb. 07	MT
Enanta Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	Feb. 07	CI
Transcript : Enanta Pharmaceuticals, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 09:45 AM	Jan. 10
Enanta Pharmaceuticals, Inc. Announces Retirement of Nathaniel S. Gardiner as Senior Vice President and General Counsel, Effective on or Before March 31, 2024	Dec. 26	CI
Enanta Pharmaceuticals, Inc.(NasdaqGS:ENTA) dropped from NASDAQ Biotechnology Index	Dec. 15	CI
Sector Update: Health Care Stocks Mixed Pre-Bell Friday	Nov. 24	MT
Sector Update: Health Care	Nov. 24	MT
Enanta Pharmaceuticals Files $150 Million Mixed Shelf	Nov. 24	MT
Oppenheimer Adjusts Enanta Pharmaceuticals Price Target to $21 From $25, Maintains Perform Rating	Nov. 22	MT

Chart Enanta Pharmaceuticals, Inc.

Duration

Period

More charts

Enanta Pharmaceuticals, Inc. is a clinical-stage biotechnology company dedicated to creating small molecule drugs with an emphasis on indications in virology and immunology. The Company's research and development programs are focused on respiratory syncytial virus (RSV) and chronic spontaneous urticaria (CSU). The Company discovered glecaprevir, the second of two protease inhibitors discovered and developed through its collaboration with AbbVie for the treatment of chronic infection with hepatitis C virus (HCV). Glecaprevir is co-formulated as part of AbbVie's direct-acting antiviral (DAA) combination treatment for HCV, which is marketed under the tradenames MAVYRET (U.S.) and MAVIRET (ex-U.S.) (glecaprevir/pibrentasvir). Its research and development programs are in virology, namely RSV, SARS-CoV-2 and hepatitis B virus. The Company has a research program targeting development of single agents with broader spectrum antiviral activity against both RSV and human metapneumovirus (hMPV).

Sector

Biotechnology & Medical Research

Calendar

2024-08-05 - Q3 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Enanta Pharmaceuticals, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

13.14 USD

Average target price

19.75 USD

Spread / Average Target

+50.30%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ENANTA PHARMACEUTICALS, INC.	+39.64%	278M
MODERNA, INC.	+16.59%	44.44B
LONZA GROUP AG	+41.02%	40.03B
IQVIA HOLDINGS INC.	-10.62%	37.68B
ALNYLAM PHARMACEUTICALS, INC.	+29.92%	31.46B
CELLTRION, INC.	-9.23%	27.29B
ICON PUBLIC LIMITED COMPANY	+12.34%	26.29B
UNITED THERAPEUTICS CORPORATION	+41.53%	13.8B
MEDPACE HOLDINGS, INC.	+31.49%	12.46B
BIO-TECHNE CORPORATION	-7.40%	11.26B

Other Biotechnology & Medical Research